Tempus completes acquisition of ambry genetics

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced it has completed its acquisition of ambry genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. “this acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cut.
TEM Ratings Summary
TEM Quant Ranking